Abiopharma

Waiver: APPLICATION TO ACRA FOR AN EXTENSION OF TIME

Castle Biosciences - New Analysis of 13,560 Patients DemonstratesDecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

General Announcement: ISSUANCE OF SHARES PURSUANT TO EXERCISE OF WARRANTS

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ symbol attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

Director Xia Yu 🟢 acquired 533.6K shares of Summit Therapeutics Inc. (SMMT) at $18.74 ($10.0M) Transaction Date: Oct 21, 2025 | Filing ID: 000004

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

QuidelOrtho Corporation - Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics

Informatics Illuminated: Science Bytes Podcast Explores the Power Behind Smarter Diagnostics

ResMed Inc. Daily Stock Update